ARCA biopharma receives method patent for treatment with bucindolol predicated on genetic targeting ARCA biopharma, Inc. , a biopharmaceutical company developing genetically targeted treatments for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for determining whether to manage or prescribe bucindolol to a patient based on if the patient has a specific genotype – homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor. The patent entitled ‘Methods for Treatment with Bucindolol Based on Genetic Targeting,’ provides intellectual real estate protection in the usa for this novel method of treating sufferers with bucindolol.The EAPC Study Network and the recently established European Palliative Treatment Research Centre shall also end up being at the congress, presenting future studies and an upcoming worldwide PhD in palliative treatment.
10 dire outcomes of Obama’s re-election victory What does an Obama re-election imply for the next four years in the us? Now that he’s in his second and last term, of program, Obama no needs to restrain his actions according to popularity longer. He can simply unleash any desired executive order and rule by decree, bypassing Congress as this individual has promised to accomplish frequently. This puts America in an exceedingly dangerous situation, given Obama’s well-demonstrated desire to eliminate independence and liberty in this country. Remember: Obama is anti wellness freedom, anti food freedom, anti GMO labeling, anti medical independence and anti farm freedom.